Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ALO-02

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
2017
2017
Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
Abstract Objective. To evaluate the abuse potential of ALO-02, an abuse-deterrent formulation comprising pellets of extended… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2017
Review
2017
Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe…
BackgroundThe efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users
ABSTRACT Background: ALO-02, comprising pellets of extended-release oxycodone surrounding sequestered naltrexone, is intended to… Expand
Is this relevant?
2015
2015
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain…
The objective of this multicenter, double-blind, placebo-controlled, randomized withdrawal study was to evaluate the efficacy and… Expand
Is this relevant?
2015
2015
Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
ALO-02 is an abuse-deterrent formulation consisting of capsules filled with pellets of extended-release oxycodone surrounding… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02)
Background and ObjectivesALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
WHAT IS KNOWN AND OBJECTIVE ALO-02 is being developed as an abuse-deterrent formulation of extended-release oxycodone… Expand
Is this relevant?
2014
2014
A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic…
OBJECTIVE To evaluate the long-term safety of oxycodone-hydrochloride and sequestered naltrexone-hydrochloride (ALO-02… Expand
Is this relevant?
Review
2014
Review
2014
Relative Bioavailability Study of an Abuse-Deterrent Formulation ofExtended-Release Oxycodone with Sequestered Naltrexone (ALO-02)Versus Immediate-Release Oxycodone Tablets in Healthy Volunteers
Background: ALO-02, an opioid formulation intended to deter abuse, comprising capsules filled with pellets of extended-release… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE